Overexpression of Runt-Related Transcription Factor-2 Is Associated with Advanced Tumor Progression and Poor Prognosis in Epithelial Ovarian Cancer

<table>Immunohistochemical staining for RUNX2 in epithelial ovarian cancer and normal ovarian tissues (original magnification ×200). (a) High RUNX2 expression (<svg height="11.225" id="M9" style="vertical-align:-0.27588pt" version="1.1" viewbox="0 0 61.612499 11.225" width="61.612499" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.225)">
<g transform="translate(72,-63.02)">
<text transform="matrix(1,0,0,-1,-71.95,63.35)">
<tspan style="font-size: 12.50px; " x="0" y="0">L</tspan>
<tspan style="font-size: 12.50px; " x="7.6393328" y="0">I</tspan>
<tspan style="font-size: 12.50px; " x="15.266163" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="27.306553" y="0">9</tspan>
<tspan style="font-size: 12.50px; " x="33.558052" y="0">6</tspan>
<tspan style="font-size: 12.50px; " x="39.809551" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="42.935303" y="0">5</tspan>
</text>
</g>
</g>
</svg>%) in epithelial ovarian cancer tissues with clinical stage IV. (b) Low RUNX2 expression (<svg height="11.0375" id="M10" style="vertical-align:-0.17555pt" version="1.1" viewbox="0 0 61.612499 11.0375" width="61.612499" xmlns="http://www.w3.org/2000/svg">
<g transform="matrix(1.25,0,0,-1.25,0,11.0375)">
<g transform="translate(72,-63.17)">
<text transform="matrix(1,0,0,-1,-71.95,63.4)">
<tspan style="font-size: 12.50px; " x="0" y="0">L</tspan>
<tspan style="font-size: 12.50px; " x="7.6393328" y="0">I</tspan>
<tspan style="font-size: 12.50px; " x="15.266163" y="0">=</tspan>
<tspan style="font-size: 12.50px; " x="27.306553" y="0">1</tspan>
<tspan style="font-size: 12.50px; " x="33.558052" y="0">6</tspan>
<tspan style="font-size: 12.50px; " x="39.809551" y="0">.</tspan>
<tspan style="font-size: 12.50px; " x="42.935303" y="0">6</tspan>
</text>
</g>
</g>
</svg>%) in epithelial ovarian cancer tissues with clinical stage I. RUNX2 immunoreactivity was predominantly localized in the nuclei of epithelial ovarian cancer cells. (c) Negative control without the primary antibody in epithelial ovarian cancer tissues. (d) Negative RUNX2 expression in normal ovarian tissues.</table>

BioMed Research International

fig1

Figure 1

Figure 1: Overexpression of Runt-Related Transcription Factor-2 Is Associated with Advanced Tumor Progression and Poor Prognosis in Epithelial Ovarian Cancer 

Figure 1 | Overexpression of Runt-Related Transcription Factor-2 Is Associated with Advanced Tumor Progression and Poor Prognosis in Epithelial Ovarian Cancer 